- Companies
- Alleviant Medical
Alleviant Medical Valuation, Funding & Investors
Alleviant Medical is valued at $260M as of January 2025.
Last Alleviant Medical valuation
$260M
Undisclosed stage · Jan 2025
Last Alleviant Medical funding round
$90M
Undisclosed stage · Jan 2025
Cumulative funding Alleviant Medical raised
$177M
across 3 funding rounds
Key investors in Alleviant Medical
S3 Ventures
RiverVest
Vensana Capital
TMC Venture Fund
Longview Ventures
Gilmartin Capital LLC
About Alleviant Medical
Alleviant Medical develops the Alleviant Heart Stabilizer, a transcatheter mitral valve repair device for congestive heart failure patients. Inserted via femoral artery access, the implant reshapes the mitral annulus to reduce regurgitation and improve cardiac output. Targeting the 6 million US heart failure cases, the system aims to cut hospital readmissions by 50 percent in clinical trials. Based in Tampa, Florida, the company raised Series A funding in 2021 and plans FDA pivotal studies.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$260M (Jan 2025)
Sectors
Alleviant Medical Valuation
Alleviant Medical is currently valued at $260M, based on its undisclosed-stage round in January 2025.
The $90M round was led by Gilde Healthcare, with participation from Gilmartin Capital LLC, S3 Ventures, Vensana Capital, RiverVest, Omega Funds and 2 other investors.
Alleviant Medical valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jan 2025 | Undisclosed stage | $260M |
Alleviant Medical Funding History
Alleviant Medical has raised a total of $177M across 3 funding rounds.
Alleviant Medical's first fundraising round was a $13M Series A in May 2020. The most recent completed round was a $90M undisclosed-stage round in January 2025.
Alleviant Medical funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2025 | Undisclosed stage | Gilde Healthcare (lead); Gilmartin Capital LLC; S3 Ventures; Vensana Capital; RiverVest; Omega Funds; Longview Ventures; TMC Venture Fund | $90M | $260M | Alleviant Medical is a privately held medical device company headquartered in Austin, Texas, developing minimally invasive therapies to treat heart failure. The company's flagship product is a no-implant atrial shunt system designed to alleviate excess pressure within the heart through a one-time procedure with no permanent implant remaining. The Alleviant System has received U.S. FDA Breakthrough Device designation for both major forms of heart failure: HFpEF (heart failure with preserved ejection fraction) and HFrEF (heart failure with reduced ejection fraction). On January 14, 2025, Alleviant Medical closed a Series D funding round of $90 million led by Gilde Healthcare. The round also included new investor Omega Funds and participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors. The company was valued at $260.0 million post-money as of the funding date. Total capital raised across all rounds reached $189.1 million. The Series D funding will support the company's second pivotal clinical trial, ALLAY-HFrEF, which will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction in the atrial shunt space. This trial represents a significant de-risking of the clinical program and positions Alleviant to address a substantial market opportunity, as heart failure is a leading cause of mortality and hospitalizations in the United States, with estimated annual healthcare costs of $70 billion. CEO Adam Berman emphasized the company's commitment to developing effective, minimally invasive treatments for the full spectrum of chronic heart failure, supported by a syndicate of prominent healthcare investors. |
| Jan 2023 | Undisclosed stage | RiverVest (lead); S3 Ventures (lead); Gilmartin Capital LLC; Vensana Capital; Shangbay Capital; Longview Ventures; TMC Venture Fund | $74M | - | Alleviant Medical is a privately held medical device company developing a no-implant interatrial shunt for the treatment of heart failure. The company closed a $75 million Series C equity financing on January 26, 2023, co-led by S3 Ventures and RiverVest Venture Partners, with participation from Vensana Capital, Longview Ventures, TMC Venture Fund, and strategic investors. The financing was used to fund the company's pivotal clinical trial program, and the round coincided with FDA IDE (Investigational Device Exemption) approval for Alleviant's pivotal clinical trial. The company's total funding reached $189 million across all rounds. |
| May 2020 | Series A | Broadview Ventures | $13M | - | Alleviant Medical is a medical device company developing a no-implant interatrial shunt system for heart failure treatment. In 2020, Longview Ventures, an affiliate of Broadview Ventures, invested in the company's $20M Series B round to fund first-in-human and additional clinical studies. The round supported advancement of the Alleviant System, which has received U.S. FDA Breakthrough Device designation for heart failure. Broadview Ventures' portfolio, including Alleviant Medical, saw co-investments and follow-on financings totaling $318M across companies in 2020. Longview Ventures, a $100M fund for follow-on investments in select Broadview portfolio companies, participated in Alleviant Medical's Series B alongside its investment in AtaCor Medical's $25M Series B. |
Who has invested in Alleviant Medical?
10 investors have backed Alleviant Medical across its funding rounds, including S3 Ventures, RiverVest, Vensana Capital, TMC Venture Fund, Longview Ventures and Gilmartin Capital LLC.
Lead investors include Gilde Healthcare, RiverVest and S3 Ventures.
Alleviant Medical Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Jan 2023 | ||
| 2 | Lead | Jan 2023 | ||
| 2 | Participant | Jan 2023 | ||
| 2 | Lead | Jan 2023 | ||
| 2 | Participant | Jan 2023 | ||
| 2 | Participant | Jan 2023 | ||
| 1 | Participant | May 2020 | ||
| 1 | Participant | Jan 2023 | ||
This data is available for Pro users. Sign up to see all 10 Alleviant Medical investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAlleviant Medical Competitors
Alleviant Medical competitors include listed companies like Tess Holdings Co, Medipost and Dong-A ST, and private ones like Unlearn.AI, Restor3d and Convergent Therapeutics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $236M | $37M | $262M | 2.2x | ||
| Private | - | - | $265M | - | ||
| Publicly listed | $54M | ($59M) | $255M | 4.7x | ||
| Private | - | - | $266M | - | ||
| Private | - | - | $269M | - | ||
| Publicly listed | $589M | $6M | $251M | 0.8x |
Alleviant Medical Public Comps
Alleviant Medical is still privately-owned, but its public comps include Tess Holdings Co, Surgical Science, Medipost, Dong-A ST, InfuSystem, Anbio Biotechnology, NN, OraSure, Anika Therapeutics and Eurobio Scientific.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $236M | $37M | 3.1x | 2.2x | 19.8x | - | |||
| $101M | $18M | 1.9x | 1.9x | 11.2x | 9.4x | |||
| $54M | ($59M) | 4.3x | 4.7x | (3.9x) | (9.7x) | |||
| $589M | $6M | 0.8x | 0.8x | 84.0x | 10.1x | |||
| $143M | $25M | 1.9x | 1.9x | 10.7x | 8.5x | |||
| $9M | $6M | 26.8x | - | 37.1x | - | |||
| $422M | $17M | 1.4x | 1.3x | 34.5x | 10.5x | |||
| $115M | ($55M) | 0.8x | 0.8x | (1.7x) | (2.2x) | |||
This data is available for Pro users. Sign up to see all Alleviant Medical competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Alleviant Medical
| When was Alleviant Medical founded? | Alleviant Medical was founded in 2017. |
| Where is Alleviant Medical headquartered? | Alleviant Medical is headquartered in Austin, TX, United States. |
| Is Alleviant Medical publicly listed? | No, Alleviant Medical is a private, VC-backed company. |
| What is Alleviant Medical's valuation? | Alleviant Medical was last valued at $260M in its undisclosed-stage round in January 2025. |
| How much funding has Alleviant Medical raised? | Alleviant Medical has raised $177M across 3 funding rounds. |
| What was Alleviant Medical's last funding round? | Alleviant Medical's last funding round was a $90M undisclosed-stage round in January 2025, led by Gilde Healthcare. |
| Who are Alleviant Medical's investors? | Alleviant Medical's investors include Gilmartin Capital LLC, S3 Ventures, Vensana Capital, RiverVest, Longview Ventures, TMC Venture Fund, Broadview Ventures, Shangbay Capital, Gilde Healthcare and Omega Funds. |
| Which companies are comparable to Alleviant Medical? | Companies comparable to Alleviant Medical include Tess Holdings Co, Unlearn.AI, Medipost, Restor3d, Convergent Therapeutics and Dong-A ST. |
See companies similar to Alleviant Medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




